Tag Archives: BMS

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Posted in Corporate Responsibility, Deals, Emerging Markets, Global, IP, Market Access, pricing | Also tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

New Non-Profit Alliance of Big Pharma Firms

By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Judge Throws The Book At Former Bristol-Myers Squibb Exec

Media wordsmiths are competing to outdo one another today in punny reporting on the news that ex-BMS exec Andrew Bodnar has been sentenced to write a book about the role he played in the firm’s 2006 reverse-payments case over generic Plavix. “Pen-ance: Bristol-Myers Exec Gets Two Years of Hard Writing,” The Wall Street Journal Law […]
Posted in Legal | Also tagged , , , , , , , | Leave a comment

Icahn to BMS: Offer is Inadequate

In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough. He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head […]
Posted in Biotech, Deals, Strategy | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta